HomeCompareALBO vs PM

ALBO vs PM: Dividend Comparison 2026

ALBO yields 4.53% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PM wins by $22.7K in total portfolio value
10 years
ALBO
ALBO
● Live price
4.53%
Share price
$44.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$605.56
Full ALBO calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — ALBO vs PM

📍 PM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALBOPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALBO + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALBO pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALBO
Annual income on $10K today (after 15% tax)
$385.05/yr
After 10yr DRIP, annual income (after tax)
$514.73/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, PM beats the other by $1,603.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALBO + PM for your $10,000?

ALBO: 50%PM: 50%
100% PM50/50100% ALBO
Portfolio after 10yr
$38.2K
Annual income
$1,548.79/yr
Blended yield
4.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

ALBO
Analyst Ratings
7
Buy
5
Hold
Consensus: Buy
Price Target
$44.00
-0.3% upside vs current
Range: $42.00 — $48.00
Altman Z
0.5
Piotroski
4/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALBO buys
0
PM buys
0
No recent congressional trades found for ALBO or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALBOPM
Forward yield4.53%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$26.9K$49.6K
Annual income after 10y$605.56$2,492.02
Total dividends collected$5.3K$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$44.00$194.30

Year-by-year: ALBO vs PM ($10,000, DRIP)

YearALBO PortfolioALBO Income/yrPM PortfolioPM Income/yrGap
1← crossover$11,153$453.00$11,648$408.29$495.00PM
2$12,406$472.18$13,589$495.90$1.2KPM
3$13,765$490.86$15,877$603.21$2.1KPM
4$15,238$509.01$18,580$734.88$3.3KPM
5$16,831$526.60$21,781$896.75$5.0KPM
6$18,553$543.61$25,578$1,096.12$7.0KPM
7$20,411$560.02$30,092$1,342.17$9.7KPM
8$22,416$575.82$35,470$1,646.46$13.1KPM
9$24,576$591.00$41,892$2,023.58$17.3KPM
10$26,902$605.56$49,578$2,492.02$22.7KPM

ALBO vs PM: Complete Analysis 2026

ALBOStock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Full ALBO Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this ALBO vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALBO vs SCHDALBO vs JEPIALBO vs OALBO vs KOALBO vs MAINALBO vs MOALBO vs BTIALBO vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.